Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study (Q37270882)

19 August 2017

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study (English)

1 reference

multicenter clinical trial

19 August 2017

0 references

masitinib

1 reference

ChEBI release 2020-05-28

1 reference

12

1 reference

19 August 2017

6

Xavier Le Loët

0 references

Patrice Dubreuil

object named as

Patrice Dubreuil

11

0 references

Xavier Mariette

2

object named as

Xavier Mariette

1 reference

19 August 2017

Jacques Tebib

1

1 reference

19 August 2017

Pierre Bourgeois

3

1 reference

19 August 2017

René-Marc Flipo

4

1 reference

19 August 2017

Philippe Gaudin

5

1 reference

19 August 2017

Paul Gineste

7

1 reference

19 August 2017

Laurent Guy

8

1 reference

19 August 2017

Colin D Mansfield

9

1 reference

19 August 2017

Alain Moussy

10

1 reference

19 August 2017

Jean Sibilia

13

1 reference

19 August 2017

language of work or name

1 reference

23 June 2009

1 reference

Arthritis Research and Therapy

19 August 2017

1 reference

19 August 2017

11

1 reference

19 August 2017

3

1 reference

19 August 2017

R95

1 reference

https://scigraph.springernature.com/pub.10.1186/ar2740

19 August 2017

0 references

cites work

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Synovial mast cells: role in acute and chronic arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Stem cell factor and its receptor c-Kit as targets for inflammatory diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Mast cells as a target of rheumatoid arthritis treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Mast cells: a cellular link between autoantibodies and inflammatory arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Rational use of new and existing disease-modifying agents in rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Tria

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2714151

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19549290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19549290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19549290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/AR2740

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19549290

1 reference